HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.

Abstract
Metastatic melanoma has poor prognosis and is refractory to most conventional chemotherapies. The alkylating agent temozolomide (TMZ) is commonly used in treating melanoma but has a disappointing response rate. Agents that can act cooperatively with TMZ and improve its efficacy are thus highly sought after. The BH3 mimetic ABT-737, which can induce apoptosis by targeting pro-survival Bcl-2 family members, has been found to enhance the efficacy of many conventional chemotherapeutic agents in multiple cancers. We found that combining TMZ and ABT-737 induced strong synergistic apoptosis in multiple human melanoma cell lines. When the drugs were used in combination in a mouse xenograft model, they drastically reduced tumor growth at concentrations where each individual drug had no significant effect. We found that TMZ treatment elevated p53 levels, and that the pro-apoptotic protein Noxa was elevated in TMZ/ABT-737 treated cells. Experiments with shRNA demonstrated that the synergistic effect of TMZ and ABT-737 was largely dependent on Noxa. Experiments with nutlin-3, a p53 inducer, demonstrated that p53 induction was sufficient for synergistic cell death with ABT-737 in a Noxa-dependent fashion. However, p53 was not necessary for TMZ/ABT-737 synergy as demonstrated by a p53-null line, indicating that TMZ and ABT-737 together induce Noxa in a p53-independent fashion. These results demonstrate that targeting anti-apoptotic Bcl-2 members is a promising method for treating metastatic melanoma, and that clinical trials with TMZ and Bcl-2 inhibitors are warranted.
AuthorsSteven N Reuland, Nathaniel B Goldstein, Katie A Partyka, David A Cooper, Mayumi Fujita, David A Norris, Yiqun G Shellman
JournalPloS one (PLoS One) Vol. 6 Issue 8 Pg. e24294 ( 2011) ISSN: 1932-6203 [Electronic] United States
PMID21897876 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • ABT-737
  • Alkylating Agents
  • Biphenyl Compounds
  • Nitrophenols
  • PMAIP1 protein, human
  • Piperazines
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • Tumor Suppressor Protein p53
  • Dacarbazine
  • Temozolomide
Topics
  • Alkylating Agents (pharmacology)
  • Animals
  • Apoptosis (drug effects)
  • Biomimetic Materials (pharmacology)
  • Biphenyl Compounds (pharmacology)
  • Cell Line, Tumor
  • Dacarbazine (analogs & derivatives, pharmacology)
  • Drug Synergism
  • Female
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Melanoma (pathology)
  • Mice
  • Nitrophenols (pharmacology)
  • Piperazines (pharmacology)
  • Protein Structure, Tertiary
  • Proto-Oncogene Proteins c-bcl-2 (metabolism)
  • Sulfonamides (pharmacology)
  • Temozolomide
  • Time Factors
  • Tumor Suppressor Protein p53 (metabolism)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: